[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342097-105":3,"doc-detail-342097-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","combination-immunotherapy-with-radiotherapy-in-non-small-cell-lung-cancer-a-review-of-evidence","Combination Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer - A Review of Evidence","","Radiotherapy is foundational across all stages of non-small-cell lung cancer (NSCLC), and immune checkpoint inhibitors (ICIs) have reshaped standard care. ICIs are increasingly used with chemoradiotherapy or surgery in definitive settings and remain central in metastatic disease. Immunotherapy monotherapy yields limited overall response rates and resistance susceptibility, prompting interest in combining radiation with ICIs to boost response and outcomes. This review synthesizes PubMed evidence on combinatorial strategies and discusses crucial treatment timing.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/combination-immunotherapy-with-radiotherapy-in-non-small-cell-lung-cancer-a-review-of-evidence/342097/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/combination-immunotherapy-with-radiotherapy-in-non-small-cell-lung-cancer-a-review-of-evidence/342097.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is combining radiotherapy with immune checkpoint inhibitors important in NSCLC?","Question",{"text":63,"@type":64},"Radiotherapy is already central in NSCLC treatment, while ICIs have transformed care but monotherapy can show limited overall response and resistance. Combining approaches is explored to enhance response rates and improve outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the authors search the evidence for this review?",{"text":68,"@type":64},"The review queried the English PubMed database using combinations of terms related to radiation, chemoradiation, immune checkpoint, immunotherapy, stereotactic body radiotherapy, and non-small-cell lung, including alternative wording for key concepts.",{"name":70,"@type":61,"acceptedAnswer":71},"What do the reviewed studies suggest about the combination’s effectiveness?",{"text":72,"@type":64},"Preclinical and clinical studies indicate additive or synergistic effects between radiation and immunotherapy across multiple NSCLC settings, with timing of treatment modalities highlighted as crucial for optimizing outcomes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342097,1790999996,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd",8,"Cancer Medicine  \n|  REVIEW  OPEN ACCESS \u003Cbr>Combination Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer: A Review of Evidence\u003Cbr>Justin L. Burr1  | Kurtis C. Johnson1  | Joseph J. Carmicheal1  | Chi Lin1  | Apar Kishor Ganti2 \u003Cbr>1Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska, USA | 2Division of Hematology-Oncology, Department of\u003Cbr>Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA Correspondence: Apar Kishor Ganti ([aganti@unmc.edu](aganti@unmc.edu)) | Chi Lin ([clin@unmc.edu](clin@unmc.edu))\u003Cbr>Received: 12 December 2023 | Revised: 18 October 2024 | Accepted: 24 October 2024\u003Cbr>Funding: The authors received no specific funding for this work. |  |\n| --- | --- |\n| ABSTRACT\u003Cbr>Background: Radiotherapy plays a fundamental role in the treatment of patients with all stages of non-small-cell lung cancer (NSCLC). The emergence of immune checkpoint inhibitors (ICIs) has transformed the standard of care in these patients. The use of ICIs is increasingly utilized in the definitive setting as an adjunct to chemoradiotherapy or surgery and remains a vital component in the treatment of metastatic disease. Despite improvements in patient survival, the use of immunotherapy as monotherapy has shown limited overall response rates with susceptibility to resistance. Radiotherapy has been identified as a viable option to enhance the response rate to ICI and improve outcomes in NSCLC.\u003Cbr>Methods: We queried the English PubMed database utilizing variably combined search items including “radiation,” “chemoradiation,” “immune checkpoint,” “immunotherapy,” “stereotactic body radiotherapy,” and “non-small-cell lung”. We additionally searched various acceptable alternative terms for similar keywords such as “radiotherapy” in place of “radiation.” These results were subsequently curated for relevance and impact on current treatment paradigms.\u003Cbr>Results: In this review, we discuss preclinical and clinical studies relating to combinatorial use of immunotherapy and radiation in NSCLC. These studies are presented in the context of early-stage, operable stage III, unresectable stage III, and metastatic disease. The majority of the data illustrate promising results regarding the additive or synergistic effects of radiation and immunotherapy with a suggestion that the timing of these treatment modalities is crucial to optimizing outcomes.\u003Cbr>Conclusion: While there is now evidence regarding the favorable interplay between radiation and immunotherapy in NSCLC, there remain multiple unanswered questions which are expected to be addressed in ongoing clinical trials. |  |\n| 1 | Introduction | immunotherapy have been demonstrated in patients with advanced NSCLC [2–5] . |\n| Cytotoxic chemotherapy and radiation have long been main- |  |\n| stays in the management of patients with non-small-cell | Recent trials have demonstrated a benefit of the addition of |\n| lung cancer. However, since first report of durable responses | immunotherapy in operable and nonoperable settings [6, 7]. |\n| to nivolumab in heavily pretreated patients with advanced | Radiotherapy continues to represent a vital component when |\n| non-small-cell lung cancer (NSCLC) [1], immune checkpoint | treating patients with early-stage, advanced-stage, and meta- |\n| inhibitors have revolutionized the management of NSCLC. | static NSCLC. There have been several anecdotal reports on |\n| The benefits of combining cytotoxic chemotherapy with | the possible benefits of the combination of radiotherapy with |\n| Justin L. Burr and Kurtis C. Johnson contributed equally to this article. |  |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd. |  |\n\nCancer Medicine, 2024; 13:e70402 1 of 11  \n[https://doi.","cbCaiaFudKQw9BeP","https://ap.wps.com/l/cbCaiaFudKQw9BeP","pdf",2228836,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n# The Evolution of Immune Checkpoint Inhibition","[{\"question\":\"Why is combining radiotherapy with immune checkpoint inhibitors important in NSCLC?\",\"answer\":\"Radiotherapy is already central in NSCLC treatment, while ICIs have transformed care but monotherapy can show limited overall response and resistance. Combining approaches is explored to enhance response rates and improve outcomes.\"},{\"question\":\"How did the authors search the evidence for this review?\",\"answer\":\"The review queried the English PubMed database using combinations of terms related to radiation, chemoradiation, immune checkpoint, immunotherapy, stereotactic body radiotherapy, and non-small-cell lung, including alternative wording for key concepts.\"},{\"question\":\"What do the reviewed studies suggest about the combination’s effectiveness?\",\"answer\":\"Preclinical and clinical studies indicate additive or synergistic effects between radiation and immunotherapy across multiple NSCLC settings, with timing of treatment modalities highlighted as crucial for optimizing outcomes.\"}]","Combination Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer - A Review of Evidence | PDF",1790045176,28,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af0efd99978cd984c6647e6c04fc7471.webp",983,1291,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/100b5733ae0218856fb59863ad25635e.webp",982,1290,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ffe6a3d670835e32ec23e9c40c7c1b70.webp",981,1289,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e6e7af27ecc8fb1d658a9be266974b3.webp",980,1287,{"code":4,"msg":82,"data":117},[118,122,126,130,135,140,144,147,152,155,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":141,"show_sort_weight":142,"slug":143},"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":145,"slug":146},30,"research-report",{"id":148,"doc_module":4,"doc_module_name":25,"category_name":149,"show_sort_weight":150,"slug":151},9,"Religion & Spirituality",20,"religion-spirituality",{"id":150,"doc_module":4,"doc_module_name":25,"category_name":153,"show_sort_weight":150,"slug":154},"World Cup","world-cup",{"id":156,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":156,"slug":158},10,"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":131,"slug":162},19,"General","general"]